Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Now Covered by Analysts at Cantor Fitzgerald

Cantor Fitzgerald started coverage on shares of Actinium Pharmaceuticals (NYSEAMERICAN:ATNMGet Rating) in a report released on Thursday morning, The Fly reports. The brokerage issued an overweight rating and a $20.00 price target on the biotechnology company’s stock.

Separately, B. Riley assumed coverage on shares of Actinium Pharmaceuticals in a research note on Thursday, August 25th. They issued a buy rating and a $16.00 price objective on the stock. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of Buy and a consensus price target of $26.20.

Actinium Pharmaceuticals Trading Up 8.9 %

NYSEAMERICAN ATNM opened at $8.18 on Thursday. Actinium Pharmaceuticals has a 1-year low of $4.41 and a 1-year high of $10.30.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNMGet Rating) last posted its quarterly earnings data on Friday, August 12th. The biotechnology company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.10). The firm had revenue of $0.05 million for the quarter, compared to analyst estimates of $1.85 million. Actinium Pharmaceuticals had a negative return on equity of 32.48% and a negative net margin of 2,165.56%. As a group, analysts forecast that Actinium Pharmaceuticals will post -1.14 EPS for the current fiscal year.

Institutional Investors Weigh In On Actinium Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. increased its stake in Actinium Pharmaceuticals by 1.1% in the 1st quarter. BlackRock Inc. now owns 230,950 shares of the biotechnology company’s stock valued at $1,180,000 after buying an additional 2,618 shares during the last quarter. Blair William & Co. IL increased its stake in shares of Actinium Pharmaceuticals by 5.5% during the 4th quarter. Blair William & Co. IL now owns 86,866 shares of the biotechnology company’s stock worth $522,000 after purchasing an additional 4,500 shares during the last quarter. State Street Corp increased its stake in shares of Actinium Pharmaceuticals by 12.5% during the 1st quarter. State Street Corp now owns 63,015 shares of the biotechnology company’s stock worth $322,000 after purchasing an additional 7,023 shares during the last quarter. Corton Capital Inc. acquired a new position in shares of Actinium Pharmaceuticals during the 2nd quarter worth about $78,000. Finally, Delphia USA Inc. acquired a new position in shares of Actinium Pharmaceuticals during the 2nd quarter worth about $85,000. 8.63% of the stock is currently owned by institutional investors and hedge funds.

Actinium Pharmaceuticals Company Profile

(Get Rating)

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.

Featured Articles

The Fly logo

Analyst Recommendations for Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)

Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.